Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation

Eurocord, Pediatric Working Party of the European Society for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, Fabio Ciceri, Sara Marktel

Research output: Contribution to journalArticle

Abstract

Despite advances in supportive therapy to prevent complications of sickle cell disease (SCD), access to care is not universal. Hematopoietic cell transplantation is, to date, the only curative therapy for SCD, but its application is limited by availability of asuitable HLA-matched donor and lack of awareness of the benefits of transplant. Included in this study are 1000 recipients of HLA-identical sibling transplants performed between 1986 and 2013 and reported to the European Society for Blood and Marrow Transplantation, Eurocord, and the Center for International Blood and Marrow Transplant Research. The primary endpoint was event-free survival, defined as being alive without graft failure; risk factors were studied using a Cox regression models. Themedian age at transplantation was 9 years, and themedian follow-up was longer than 5 years. Most patients received amyeloablative conditioning regimen (n = 873; 87%); the remainder received reduced-intensity conditioning regimens (n = 125; 13%). Bonemarrow was the predominant stem cell source (n = 839; 84%); peripheral blood and cord blood progenitors were used in 73 (7%) and 88 (9%) patients, respectively. The 5-year event-free survival and overall survival were 91.4% (95% confidence interval, 89.6%-93.3%) and 92.9% (95% confidence interval, 91.1%-94.6%), respectively. Eventfree survival was lower with increasing age at transplantation (hazard ratio [HR], 1.09; P
Original languageEnglish
Pages (from-to)1548-1556
Number of pages9
JournalBlood
Volume129
Issue number11
DOIs
Publication statusPublished - 2017

    Fingerprint

Cite this

Eurocord, Pediatric Working Party of the European Society for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, Ciceri, F., & Marktel, S. (2017). Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood, 129(11), 1548-1556. https://doi.org/10.1182/blood-2016-10-745711